Novo Nordisk A/S (BSP:N1VO34) ROE % Adjusted to Book Value : 24.28% (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Novo Nordisk A/S ROE % Adjusted to Book Value?

Novo Nordisk A/S's ROE % for the quarter that ended in Dec. 2023 was 88.63%. Novo Nordisk A/S's PB Ratio for the quarter that ended in Dec. 2023 was 3.65. Novo Nordisk A/S's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 was 24.28%.

Novo Nordisk A/S ROE % Adjusted to Book Value Historical Data

The historical data trend for Novo Nordisk A/S's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novo Nordisk A/S ROE % Adjusted to Book Value Chart

Novo Nordisk A/S Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

40.09

24.47

21.11

23.69

Novo Nordisk A/S Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															21.98	25.64	26.09	25.14	24.28

Competitive Comparison of Novo Nordisk A/S's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Novo Nordisk A/S's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Novo Nordisk A/S's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Novo Nordisk A/S's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Novo Nordisk A/S's ROE % Adjusted to Book Value falls into.

Novo Nordisk A/S ROE % Adjusted to Book Value Calculation

Novo Nordisk A/S's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	86.48%	/	3.65
	=	23.69%

Novo Nordisk A/S's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	88.63%	/	3.65
	=	24.28%

Novo Nordisk A/S ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Novo Nordisk A/S's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Novo Nordisk A/S (BSP:N1VO34) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novo Nordisk A/S (BSP:N1VO34) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

NONOF:USA NVO:USA NOVOB:Mexico NVO:Mexico NOVOBc:UK 0QIU:UK NOVO B:Denmark NOV:Germany NNO2:Austria

Address

Novo Alle 1, Bagsvaerd, DNK, DK-2880

Website

https://www.novonordisk.com

With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Novo Nordisk A/S (BSP:N1VO34) Headlines

No Headlines